A perspective of plasma cell dyscrasias: Clinical implications of monoclonal light chains in renal disease

  • Alan Solomon
  • Deborah T. Weiss
Chapter
Part of the Developments in Nephrology book series (DINE, volume 22)

Abstract

The term ‘plasma cell dyscrasia’ may be interpreted broadly as any type of anatomical, developmental, or functional alteration in the B cell or humoral system. Specifically, the diseases or syndromes associated with plasma cell dyscrasias result from under or over proliferation of the most differentiated cellular elements of this system, plasma cells and their immediate B lymphocyte precursors, or from immunoglobulin (Ig) molecules which are produced by these cells and function as antibody. The plasma cell dyscrasias include a spectrum of diseases. They may be inherited or acquired, reactive or neoplastic, but all are characterized by some type of Ig alteration (Table 1). In addition, these diseases may be intrinsic to B cells only or may involve other types of cells or factors tnat control B cell growth and maturation.

Keywords

Multiple Myeloma Light Chain Plasma Cell Dyscrasia Bence Jones Protein Light Chain Deposition Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Edelman GM, Gaily JA. The nature of Bence-Jones proteins. Chemical similarities to polypeptide chains of myeloma globulins and normal γ-globulins. J Exp Med 1962; 116:207–27.PubMedCrossRefGoogle Scholar
  2. 2.
    Solomon A. Monoclonal immunoglobulins as biomarkers of cancer. In: Sell S, ed. Cancer markers: developmental and diagnostic significance. Clifton, New Jersey: Humana Press 1980:57–87.Google Scholar
  3. 3.
    Solomon A. Light chains of human immunoglobulins. Methods Enzymol 1985; 116: 101–21.PubMedCrossRefGoogle Scholar
  4. 4.
    Solomon A. Current developments in immunoglobulins. In: Silber R, Gordon AS, LoBue J, Muggia FM, eds. Contemporary hematology/oncology, Vol 2. New York: Plenum Press, 1981:399–465.Google Scholar
  5. 5.
    Yarbro JW, Bornstein RS, Mastrangelo MJ, eds. Semin oncol, Vol XIII(3). Orlando, Florida: Grune and Stratton, 1986.Google Scholar
  6. 6.
    Hill GS. Multiple myeloma, amyloidosis, Waldenstrom’s macroglobulinemia, cryoglobulinemias, and benign monoclonal gammopathies. In: Heptinstall RH, ed. Pathology of the kidney, ed. 3. Boston: Little Brown & Co, 1983: 993–1067.Google Scholar
  7. 7.
    Gallo GR, Feiner HD, Buxbaum JN. The kidney in lymphoplasmacytic disorders. Pathol Annu 1982; 17:291–317.PubMedGoogle Scholar
  8. Pirani CL, Silva FG, Appel GB. Tubulo-interstitial disease in multiple myeloma and other nonrenal neoplasias. In: Cotran AS, ed. Tubulo-interstitial nephropathies, contemporary issues in nephrology, Vol 10. New York: Churchill-Livingstone, 1983: 287–334.Google Scholar
  9. 9.
    Glenner GG. Amyloid deposits and amyloidosis: the B-fibrilloses. N Engl J Med 1980; 302: 1283–92.PubMedCrossRefGoogle Scholar
  10. 10.
    Fang LS. Light-chain nephropathy. Kidney Int 1985; 27: 882–92.CrossRefGoogle Scholar
  11. 11.
    Solomon A. Clinical implications of monoclonal light chains. Semin Oncol 1986; 13: 341–49.PubMedGoogle Scholar
  12. 12.
    Solomon A. Bence-Jones proteins and light chains of immunoglobulins. N Engl J Med 1976; 294: 17–23; 91–98.PubMedCrossRefGoogle Scholar
  13. 13.
    Wochner RD, Strober W, Waldman TA. The role of the kidney in the catabolism of Bence Jones proteins and immunoglobulin fragments. J Exp Med 1967; 126: 207–21.PubMedCrossRefGoogle Scholar
  14. 14.
    Strober W, Waldmann TA. The role of the kidney in the metabolism of plasma proteins. Nephron 1974; 13: 35–66.PubMedCrossRefGoogle Scholar
  15. 15.
    Solomon A. Bence Jones proteins: malignant or benign? (editorial). N Engl J Med 1982; 306:605–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Koss MN, Pirani CL, Osserman EF. Experimental Bence Jones cast nephropathy. Lab Invest 1976; 34: 579–91.PubMedGoogle Scholar
  17. 17.
    Solomon A. Light chains of immunoglobulins: Structural-genetic correlates. Blood 1986;68:603–10.PubMedGoogle Scholar
  18. 18.
    Solomon A, Frangione B, Franklin EC. Bence Jones proteins and light chains of immunoglobulins. Preferential association of the VλVI subgroup of human light chains with amyloidosis AL(λ). J Clinical Invest 1982; 70:453–60.CrossRefGoogle Scholar
  19. 19.
    Solomon A, Weiss DT. Serologically defined V region subgroups of human λ light chains. J Immunol 1987; 139: 824–30.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers, Dordrecht 1988

Authors and Affiliations

  • Alan Solomon
    • 1
  • Deborah T. Weiss
  1. 1.University of Tennessee Medical Center at KnoxvilleKnoxvilleUSA

Personalised recommendations